The U.S. Food and Drug Administration (FDA) approved Dovato (dolutegravir and lamivudine) for a new indication in October 2023. This approval expands its use to individuals with HIV who have no history of antiviral treatment for HIV infection. Previously, Dovato was indicated for treatment-experienced adults with HIV who had no known resistance to either of its active components [1].
What does this new indication mean for HIV treatment?
This expanded approval allows Dovato to be used as an initial treatment option for a broader population of individuals newly diagnosed with HIV. This means more patients can potentially start their HIV therapy with a single, two-drug regimen containing dolutegravir and lamivudine, aiming to simplify treatment and reduce the number of medications taken [1].
How does Dovato work?
Dovato is a combination antiretroviral therapy that contains two medications: dolutegravir and lamivudine. Dolutegravir is an integrase strand transfer inhibitor (INSTI), and lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI). These drugs work together to inhibit viral replication by interfering with different stages of the HIV life cycle [2].
When does Dovato's patent expire?
Information regarding the specific patent expiration dates for Dovato is available through resources like DrugPatentWatch.com [3]. Understanding patent exclusivity is crucial for predicting when generic versions of the drug may become available.
Are there other single-tablet HIV regimens available?
Yes, other single-tablet regimens (STRs) are approved for the treatment of HIV, offering various combinations of antiretroviral drugs. The choice of STR often depends on factors such as an individual's viral load, resistance testing, co-existing medical conditions, and potential drug interactions [4].
What are the key clinical trial findings for this new indication?
The FDA's approval was based on data from clinical trials, including the Phase III TANGO study. These trials demonstrated that Dovato was non-inferior in efficacy compared to a standard three-drug regimen in treatment-naive adults, with a similar safety profile [1].
What are the potential side effects of Dovato?
Common side effects reported in clinical trials include headache, diarrhea, nausea, insomnia, and fatigue. More serious side effects, though less common, can include hypersensitivity reactions and liver enzyme elevations. Patients should discuss any potential side effects with their healthcare provider [2].
Sources:
[1] https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-dovato-dolutegravir-and-lamivudine-tablets-initial-treatment-hiv-infection
[2] https://www.dovato.com/
[3] https://drugpatentwatch.com/
[4] https://www.aidsinfo.nih.gov/drugs/654/dovato/0/patient